TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

Verdict

Headline takes no side. We score HURA +0.80 across three claims.

Our read: bullish.

HURA score

+0.80

−1 bearish0bullish +1

More positive than 88% of ticker scores this week

Price reaction

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What matters in this story